Miniaturization of Cell-Based β-Lactamase-Dependent FRET Assays to Ultra-High Throughput Formats to Identify Agonists of Human Liver X Receptors

Assay and Drug Development Technologies

Volumn 1, Issue 6, 2003, Pages 777-787

  Chin, Jayne ^a   Adams, Alan D ^a   Bouffard, Aileen ^a   Green, Ahren ^a   Lacson, Raul G ^a   Smith, Todd ^a   Fischer, Paul A ^a   Menke, John G ^a   Sparrow, Carl P ^a   Mitnaul, Lyndon J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; BETA LACTAMASE; CELL RECEPTOR; DNA BINDING PROTEIN; LIVER X RECEPTOR;

ANIMAL; ARTICLE; CHEMISTRY; CHO CELL; DOSE RESPONSE; DRUG POTENTIATION; ELECTRONICS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HAMSTER; HUMAN; LIVER; METABOLISM; METHODOLOGY;

ANIMALS; BENZOIC ACIDS; BENZYLAMINES; BETA-LACTAMASES; CHO CELLS; CRICETINAE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LIVER; MINIATURIZATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 4944247027     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/154065803772613417     Document Type: Article

References (19)

1. Fitzgerald ML, Moore KJ, Freeman MW: Nuclear hormone receptors and cholesterol trafficking: The orphans find a new home. J Mol Med 2002;8:271–281.
2. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P: Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213–219.
3. Lund EG, Menke JG, Sparrow CP: Liver x receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23: 1169–1177.
4. Peet DJ, Janowski BA, Mangelsdorf DJ: The LXRs: A new class of oxysterol receptors. Curr Opin Genet Dev 1998;8: 571–575.
5. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG: 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001;276:38378–38387.
6. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B: Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831–2838.
7. Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM: Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem 2002;45:1963–1966.
8. Sparrow CP, Baffic J, Lam MH, Lund EG, Adams AD, Fu X, Hayes N, Jones AB, MacNaul KL, Ondeyka J, Singh S, Wang J, Zhou G, Moller DE, Wright SD, Menke JG: A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem 2002;277:10021–10027.
9. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P: Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002;99:7604–7609.
10. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T: T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 2003;536:6–11.
11. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F: Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002;277:34182–34190.
12. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ: Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998;93:693–704.
13. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem I, Pettersson S, Gustafsson JA: Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J Clin Invest 2001;107:565–573.
14. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, Whitney M, Roemer K, Tsien RY: Quantitation of transcription and clonal selection of single living cells with β-lactamase as reporter. Science 1998;279:84–88.
15. Kunapuli P, Ransom R, Murphy KL, Pettibone D, Kerby J, Grimwood S, Zuck P, Hodder P, Lacsosn R, Hoffman I, Inglese J, Strulovici B: Development of an intact cell reporter gene β-lactamase assay for G protein-coupled receptors for high-throughput screening. Anal Biochem 2003;314:16–29.
16. i protein-coupled receptors. J Recept Signal Transduct Res 2000;20:189–210.
17. Schwartz K, Lawn RM, Wade DP: ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun 2000;274:794–802.
18. Sun Y, Hao M, Luo Y, Liang CP, Silver DL, Cheng C, Maxfield FR, Tall AR: Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure. J Biol Chem 2003;278:5813–5820.
19. Peekhaus NT, Ferrer M, Chang T, Kornienko O, Schneeweis JE, Smith TS, Hoffman I, Mitnaul LJ, Chin J, Fischer PA, Blizzard TA, Birzin ET, Chan W, Inglese J, Strulovici B, Rohrer SP, Schaeffer JM: A β-lactamase dependent Gal4-estrogen receptor β transactivation assay for the ultra high throughput screening of estrogen receptor β agonists in a 3,456-well format. Assay Drug Devel Technol 1:787–798.